February 24, 2020

Resolution Bioscience and LabCorp Will Collaborate to Commercialize the Resolution ctDx Lung™Liquid Biopsy Assay

Resolution ctDx Lung assay has a demonstrated ability to provide clinically actionable results that can inform care decisions for NSCLC patients

— Resolution Bioscience, Inc., today announced an agreement with LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, to make the Resolution ctDx™ Lung assay available to clinicians and patients. The fast, accurate, and non-invasive test is designed to detect actionable mutations in non-small cell lung cancer (NSCLC) genes recommended by professional guidelines. The assay will be performed in Resolution’s CLIA laboratory as a laboratory developed test, and is expected to be available exclusively from LabCorp in the first half of 2020.

The clinical utility of the Resolution ctDx Lung assay has been successfully demonstrated in multiple clinical studies with leading cancer centers and academic research institutions, including Memorial Sloan Kettering Cancer Center, Northern Cancer Institute of Sydney, Dana-Farber Cancer Institute, and Vanderbilt University.

"We are excited to be working with LabCorp to enable broad access to our ctDx Lung assay," said Mark Li, CEO of Resolution Bioscience. "With our purpose-built cell-free DNA technology platform, we look forward to making a clinically meaningful impact for a growing number of patients."

About Resolution Bioscience’s Liquid Biopsy Technology
The Resolution liquid biopsy assays are powered by the company’s patented cell-free DNA (cfDNA) analysis platform, which includes proprietary targeted capture next-generation sequencing (NGS) biochemistry and tightly coupled, cloud-based bioinformatics. Resolution’s technology has now been recognized as novel by the FDA and has been cited in several important scientific publications and presentations.
For example:

About Resolution Bioscience
Resolution Bioscience is a privately held company dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed and patented core technology for circulating cell-free DNA NGS analysis. The company is based in Kirkland, WA. For more information, visit www.resolutionbio.com

Resolution Bioscience, the Resolution Bioscience logo, and Resolution HRD are trademarks of Resolution Bioscience, Inc. All other brands may be trademarks of their respective holders.